What's Happening With AbbVie Stock?
13/11 06:00
AbbVie stock (NYSE: ABBV) was down 12% on Monday, November 11, after the company announced that two mid-stage clinical trials of its drug Emraclidine to treat schizophrenia failed to meet their primary goal. Emraclidine was developed by Cerevel Therapeutics, which AbbVie acquired...